Is Wall Street's initial excitement giving way to more realistic expectations?
News & Analysis: Personalis, Inc.
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
A recent IPO and a small fertilizer producer appear to have been overlooked by Mr. Market, but individual investors might want to keep an eye on both.
Depending on one customer for too much revenue is generally a red flag, but the intentional growth strategy of Personalis is worth paying closer attention to.
The public markets are awash in new biopharmaceutical companies, but these two appear to be overlooked.
Wall Street might be overlooking these intriguing investing opportunities.